The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.
Canadian wildfire smoke triggers poor air quality, health advisories in Colorado – The Cannabist
Related Articles Haze blanketed Colorado on Monday as wildfire smoke drifted from Canada, and the gray skies are expected to hover overhead for at least
July 23, 2024